Globe Life (GL)
NYSEFinancialsInsurance - LifeSnapshot 2026-10-29
$159.08-0.85%
Close 2026-10-30 · 1-day change
NYSEFinancialsInsurance - LifeSnapshot 2026-10-29
Research Workspace
Put GL beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Financials is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Management is running behind on a stated commitment.
View ThesisRevenue is growing steadily — about 5% over the past year.
View GrowthMiddle-of-the-pack quality for its industry.
View QualityManagement screens strong on capital allocation, the balance sheet.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskGlobe Life's earnings growth and durable franchise must support its premium valuation. Revenue growth eased from 7% to 5%, while Q3 revenue growth is unavailable. Q3 2026 non-GAAP EPS missed consensus, and the company lowered guidance. GL trades at 2× P/B versus a 1× peer median, reflecting less growth than our forecast. A 42% modeled next-quarter miss probability threatens the earnings-guidance case. Peer multiples imply a price roughly in line with where it trades (about fair). The thesis is on watch, and this read is provisional.
Trailing returns as of 2026-10-30. GL is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 12 analysts currently covering GL (as of Oct 2026).
Based on 5 Wall Street analysts offering 12-month price targets for GL in the last 4 months.
Continue this research
Compare GL with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| GL Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 10 valuation methods, at three horizons. As of 2026-10-30. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Life & Health Insurance — fair value, gap to price, and forward P/E.
Compare the value case
Put GL next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Increase earnings per share and earnings guidance
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
Current $159.08
The last 12 months of price, then the range of analyst 12-month targets from today’s $159.08.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 25% on quality vs scored peers
A second lens on the 12-month fair value: for companies that score high on measured quality (profitability, balance-sheet safety, earnings stability), this read trusts more of today's profit margins instead of averaging them toward their multi-year history the way the headline number does. Shown alongside the fair value above, not in place of it. A diagnostic, not a price target or a buy/sell signal.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
2027 EPS and excess-cash-flow targets support earnings growth and capital-generation objectives.
Threatens: Increase EPS guidance for 2026
Earnings miss and lowered guidance directly threaten the 2026 EPS guidance objective.
Threatens: Increase EPS guidance for 2026
EPS missed expectations, weakening near-term earnings performance; revenue miss was modest.
Advances: Increase life and health net sales
Health insurance growth supports net sales objective.
Advances: Increase life and health net sales
Health insurance growth supports net sales objective.
Threatens: Repurchase shares of common stock
Weaker margins may impact share repurchase effectiveness.
Advances: Increase EPS guidance for 2026
Executive stock sale amidst strong growth outlook.
Advances: Increase EPS guidance for 2026
Raised guidance is a significant positive.